Navigation Links
Two New Drugs For Breast Cancer Show Promise

Two of the most promising breast cancer drugs are raloxifene and lapatinib, according to researchers who revealed their findings// at he European Breast Cancer Conference (EBCC-5). Raloxifene is a drug that was first developed to treat osteoporosis in women.

It belongs to a class of drugs called selective benzothiophene oestrogen receptor modulator (SERM) and exerts an anti-estrogen effect. Hence it's use in breast cancer. In the trials where raloxifene was used as an osteoporosis drug, it also appeared to prevent the formation of new hormone dependant breast cancers. The MORE (The Multiple Outcomes of Raloxifene Evaluation) study, which evaluated 7,705 women by either administering raloxifene or placebo to a group. The results of this trial are awaited. Another trial that aims to test the efficacy of raloxifene was conducted on 20,000 postmenopausal women in the US. The results of this trial are also awaited. However, women taking raloxifene are known to have an increased risk of developing deep vein thrombosis or pulmonary embolism as side effects. Another drug that is exciting researchers is lapatinib, which is given orally. The molecule is a subset of Epidermal Growth Factor Receptors (EGFR). Preliminary results suggest that the drug could kill cancer cells that are not killed by other breast cancer drugs. Dr F. Cardoso from the Jules Bordet Institute, Brussels, who is involved in the drug research said, "Raloxifene and lapatinib are exciting new drugs which will be of interest in prevention and treatment of breast cancer patients in the future." Contact: EBCC-5 Press Office stephanie.makin@toniclc.com 33-493-928-402 Federation of European Cancer Societies Source: Eurekalert
'"/>




Page: 1

Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Life Saving Cancer Drugs – From Chicken! Possible Says Dolly’ Creatos
3. Nasal Spray Could Take Drugs Direct to Brain.
4. Emphasis to ban Drugs ads by Doctors
5. Osteoporosis Drugs: right time to take-off
6. Drugs disrupt formation of blood vessels
7. Drugs to stop burgeon of HIV
8. Misleading Advertisements for Prescription Drugs
9. Drugs For Anthrax May Interfere With Oral Contraceptives
10. Over-The-Counter Drugs May Prevent Alzheimers
11. Steps To Improve Quality Of Plant-Based Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... Thailand (PRWEB) , ... August 19, 2017 , ... ... Business, Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness ... in Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and ... Houston, Texas . The Mostyn Law ... past 2 years. That is why Mostyn Law is ... to show its appreciation. Blood supplies are ... fall 5% short of hospital needs in August. That is why ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... quarter ending June 30, 2017. ... preparing for our pivotal Phase 3 trial to investigate ... , President and Chief Executive Officer of BrainStorm. "We ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
Breaking Medicine Technology: